Treatment of depression in an adolescent with cardiomyopathy and arrhythmia.
Patients with cardiomyopathy have a higher incidence of mood and anxiety disorders, resulting in greater probability for hospitalisation and increased risk for arrhythmia and death. We report a case of a 16-year-old boy with Danon disease, Wolff-Parkinson-White syndrome, and hypertrophic cardiomyopathy, who later developed depression and significant weight loss. The patient was successfully treated for his anxiety and depression with mirtazapine without any adverse cardiac effects.
1Department of Child and Adolescent Psychiatry,Child and Adolescent Psychiatry Clinic,Bakirkoy State Hospital for Mental Health and Neurological Disorders,Istanbul,Turkey.
Canan
C
Tanidir
2Department of Pediatric Cardiology,Istanbul Mehmet Akif Ersoy,Thoracic and Cardiovascular Surgery Center and Research Hospital,Istanbul,Turkey.
Ibrahim C
IC
Tanidir
3Department of Pediatric Cardiology and Electrophysiology,Pediatric and Genetic Arrhythmia Center,Istanbul Medipol University Hospital,Istanbul,Turkey.
Volkan
V
Tuzcu
D000293:Adolescent; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use*; D001007:Anxiety / Q000188:drug therapy*; D002312:Cardiomyopathy, Hypertrophic / Q000523:psychology*; D003863:Depression / Q000188:drug therapy*; D004562:Electrocardiography; D052120:Glycogen Storage Disease Type IIb / Q000523:psychology*; D006801:Humans; D008297:Male; D008803:Mianserin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000078785:Mirtazapine; D015431:Weight Loss / Q000187:drug effects; D014927:Wolff-Parkinson-White Syndrome / Q000175:diagnosis*
D000929:Antidepressive Agents, Tricyclic; D008803:Mianserin; D000078785:Mirtazapine
Arrhythmia; Danon disease; depression; hypertrophic cardiomyopathy; mirtazapine